UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2023

Acrivon Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-41551**	**82-5125532**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

480 Arsenal Way, Suite 100 **Watertown, Massachusetts** **(Address of Principal Executive Offices)**	**02472** **(Zip Code)**

(617) 207-8979
(Registrant's Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	ACRV	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On November 9, 2023, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure

On November 9, 2023, Acrivon Therapeutics, Inc. also updated its corporate presentation. A copy of the corporate presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information contained in Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit Number	Exhibit Description
99.1	Press Release dated November 9, 2023
99.2	Acrivon Therapeutics, Inc. Presentation
104	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acrivon Therapeutics, Inc.

Dated: November 9, 2023

By: /s/ Peter Blume-Jensen
Name: Peter Blume-Jensen, M.D., Ph.D.
Title: Chief Executive Officer and President

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

WATERTOWN, Massachusetts, November 9, 2023 – Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

"Acrivon remains committed to being science and data-driven as we continue advancing our clinical and preclinical pipeline of precision oncology medicines, enabled by our highly differentiated Acrivon Predictive Precision Proteomics (AP3) platform," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. "Our recent presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics further demonstrate the unique and broad capabilities of AP3 and our drug-specific OncoSignature assays. As part of our third quarter highlights, we are also pleased to provide initial clinical readouts for ACR-368 and plan to present more mature data at a major medical conference during the first half of 2024. We are also very excited about the advancement of our novel, internally-discovered development candidate ACR-2316, a dual WEE1/PKMYT1 inhibitor specifically designed by AP3 for superior, single agent activity, as demonstrated in preclinical studies compared to benchmark clinical compounds. We plan to submit an IND for ACR-2316 in the fourth quarter of 2024."

Recent Highlights

- Continued enrollment of patients in the multicenter, registrational-intent Phase 2 study based on OncoSignature-predicted sensitivity to ACR-368 in patients with locally advanced or metastatic, recurrent platinum-resistant ovarian cancer, as well as endometrial adenocarcinoma or urothelial cancer, two tumor types predicted to be sensitive to ACR-368 through OncoSignature screening and not previously evaluated in past clinical trials. Initial clinical observations are encouraging and support the ongoing trials.
    - Consistent with the overall favorable tolerability profile previously observed in multiple past single-arm trials conducted at recommended Phase 2 dose (RP2D), drug-related adverse events were primarily hematological, reversible, and manageable
    - In the limited number of patients evaluated by imaging to date, preliminary evidence of clinical activity was observed in OncoSignature-positive patients across all three tumor types treated with single agent ACR-368 at RP2D
    - Consistent with AP3-predicted tumor sensitivity to the combination of ACR-368 and low dose gemcitabine (LDG) in OncoSignature-negative patients, early imaging-based evidence of clinical activity across all three tumor types was also observed in patients treated with ACR-368 at RP2D and LDG during the dose escalation phase

- Presentation of two posters demonstrating the broader capabilities of the AP3 platform, including unbiased characterization of clinically actionable ACR-368-induced phosphoproteome alterations and extensive evaluation of the ACR-368 OncoSignature assay for patient responder identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    - The poster titled “Identification of Biomarkers Predictive of Sensitivity to the CHK1/2 Inhibitor ACR-368 Using High-Resolution Phosphoproteomics and Development of an ACR-368-Tailored Patient Responder Identification 3-Marker Test, ACR-368 OncoSignature” showed data leveraging the company’s AP3 approach, including ultra-high resolution, quantitative mass spectrometry-based phosphoproteomics profiling combined with proprietary approaches to identify three classes of functionally orthogonal candidate biomarkers specifically predictive of sensitivity to ACR-368. The company’s ACR-368-specific OncoSignature assay accurately predicted sensitivity to ACR-368 in genetically non-modified ovarian cancer patient-derived xenograft (PDX) models with an area under the curve (AUC) of 0.9 (95% confidence interval: 0.71 to 1; p-value = 0.025). These data support the use of the company’s ACR-368 OncoSignature assay in its ongoing registrational-intent Phase 2 clinical trials, and demonstrate the distinctive, practical application of the company’s AP3 platform.
    - The poster titled “Validation of the OncoSignature Assay, an ACR-368-Tailored Response-Predictive Quantitative Multiplexed Immunofluorescent Assay for Prediction of Sensitivity to the CHK1/2 Inhibitor ACR-368 in Individual Patients with Cancer” provided data validating the ability of the AP3-derived ACR-368-specific OncoSignature assay to predict tumor response to ACR-368 in multiple blinded, prospectively-designed preclinical studies, including two separate studies on pretreatment tumor biopsies from past Phase 2 clinical trials in patients with ovarian cancer and in tumor types predicted sensitive to ACR-368, including endometrial cancer. In the two pretreatment tumor biopsy studies, the ACR-368 OncoSignature test was overall able to segregate responders from non-responders with high accuracy and enrich for responders, achieving an overall response rate of 47% and 58% with strong statistical significance. Additionally, endometrial and bladder cancers were identified as new tumor types predicted sensitive to ACR-368 in 30-40% of cases.
- Continued advancement of IND-enabling studies for ACR-2316, the company’s internally discovered, selective dual WEE1 and PKMYT1 inhibitor, specifically designed using the AP3 platform and rational drug design based on co-crystallography to achieve potent single agent activity. The company anticipates IND submission in the fourth quarter of 2024 and plans to then initiate clinical monotherapy development in tumor types predicted sensitive to ACR-2316 through ongoing AP3-based indication finding and subsequent treatment of patients based on OncoSignature-predicted sensitivity.

Anticipated Upcoming Milestones

- Company plans to present more mature clinical data from the ongoing Phase 2 ACR-368 monotherapy single-arm trials and the Phase 1b/2 ACR-368 and LDG combination single-arm trials at a major medical conference during the first half of 2024
- Completion of IND-enabling studies for ACR-2316 to support IND submission for this novel drug candidate in the fourth quarter of 2024

Third Quarter 2023 Financial Results

Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.

Research and development expenses were $10.3 million for the quarter ended September 30, 2023 compared to $7.9 million for the same period in 2022. The difference was primarily due to the continued development of ACR-368, inclusive of progression of the ongoing clinical trial, as well as increased personnel costs to support these development activities and costs associated with our preclinical programs, including ACR-2316.

General and administrative expenses were $5.9 million for the quarter ended September 30, 2023 compared to $1.6 million for the same period in 2022. The difference was primarily due to the increased cost of operating as a public company, inclusive of increased personnel costs and non-cash stock compensation expense.

As of September 30, 2023, the company had cash, cash equivalents and marketable securities of $142.1 million, which is expected to fund operations into the second half of 2025.

About Acrivon Therapeutics

Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner. These distinctive capabilities enable AP3’s direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its internally-discovered preclinical stage pipeline programs, consisting of its development candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and additional programs targeting these two critical nodes in the DNA Damage Response, or DDR, pathways.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.

Investor and Media Contacts:

Adam D. Levy, Ph.D., M.B.A
alevy@acrivon.com

Alexandra Santos
asantos@wheelhouselsa.com

Acrivon Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Operating expenses:				
Research and development	$ 10,267	$ 7,942	$ 30,546	$ 18,087
General and administrative	5,870	1,633	15,504	4,625
Total operating expenses	16,137	9,575	46,050	22,712
Loss from operations	(16,137)	(9,575)	(46,050)	(22,712)
Other income (expense):				
Other income, net	1,671	377	4,914	474
Total other income, net	1,671	377	4,914	474
Net loss	$ (14,466)	$ (9,198)	$ (41,136)	$ (22,238)
Net loss per share - basic and diluted	$ (0.66)	$ (5.17)	$ (1.87)	$ (12.55)
Weighted-average common stock outstanding - basic and diluted	22,081,162	1,778,255	21,991,509	1,772,491
Comprehensive loss:				
Net loss	$ (14,466)	$ (9,198)	$ (41,136)	$ (22,238)
Other comprehensive loss:				
Unrealized gain (loss) on available-for-sale investments, net of tax	125	(133)	(207)	(133)
Comprehensive loss	$ (14,341)	$ (9,331)	$ (41,343)	$ (22,371)

Acrivon Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(unaudited, in thousands)

	September 30, 2023	December 31, 2022
Assets		
Cash and cash equivalents	$ 29,859	$ 29,519
Short-term investments	112,231	98,232
Long-term investments	—	41,881
Other assets	9,002	11,594
Total assets	$ 151,092	$ 181,226
Liabilities and Stockholders' Equity		
Liabilities	12,943	10,751
Stockholders' Equity	138,149	170,475
Total Liabilities and Stockholders' Equity	$ 151,092	$ 181,226

Exhibit 99.2


Acrivon
Therapeutics
ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3)
OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE
CORPORATE PRESENTATION
NOVEMBER 2023

FORWARD-LOOKING STATEMENTS

Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Our forward-looking statements are based primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in the forward-looking statements is subject to risks and uncertainties, including the factors described in our filings with the U.S. Securities and Exchange Commission. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this presentation. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to update any forward-looking statements or to reflect new information or the occurrence of unanticipated events, except as required by law.

ACRIVON: NEXT GENERATION PRECISION ONCOLOGY

OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE



Experienced team focused on execution with cash runway into 2H 2025

ACCOMPLISHED LEADERSHIP TEAM

Peter Blume-Jensen, M.D., Ph.D.
CEO, President, Founder

- Executive Serono, Merck & Co., Daiichi Sankyo
- CSO Metamark - Marketed prostate proteomic test ProMark®
- Inventor Acrivon Predictive Precision Proteomics (AP3)

Rasmus Holm-Jorgensen
Chief Financial Officer

- Novo Nordisk Finance and IR
- Synageva pipeline expansion and $9bn sale to Alexion
- Kiniksa founding team, IPO and commercial launch

Kristina Masson, Ph.D., M.B.A
Site Head Acrivon AB, Co-Founder
EVP Business Operations

- Cross-functional Leadership Merrimack Pharmaceuticals, MIT/BROAD
- Founder and CEO, OncoSignature AB (acquired by Acrivon Therapeutics)

Erick Gamelin, M.D., Ph.D.
Chief Medical Officer

- Professor, CEO, large national cancer center and hospital
- Executive Amgen, Pfizer, Dynavax, MacroGenics; CMO STEP Pharma
- >100 ph 1-3 oncology trials

Eric Devroe, Ph.D.
Chief Operating Officer

- Founder and CEO, Opsonix
- Business executive MD Anderson Cancer Center and Metamark
- EIR Wyss Institute, Harvard
- Associate, Flagship Pioneering

Mary-Alice Miller, J.D.
Chief Legal Officer

- Over 20 years corporat legal experience
- Served as general couns of 2 companies taken public
- Boston Business Journal "40 Under 40"

Adam Levy, Ph.D., M.B.A.
SVP, Investor Relations and Corporate Affairs

Praveen Marapaka, Ph.D.
SVP, Global Regulatory Affairs

Monica Phadnis
SVP, Clinical Operations

Karl Hsu, M.D.
SVP, Clinical Development

John van Duzer, Ph.D.
SVP, CMC

Bruce Close, M.S.
VP, Quality and Compliance

Joon Jung, Ph.D.
VP, Head, Data Science

Rajshree Kandadai, M.A.
VP, Business Development

Parvin Miah
VP, Head, Human Resources

Katie Peterson, C.P.A.
VP, Finance and Accounting

David Proia, Ph.D.
VP, Drug Discovery and Biology

Michail Shipitsin
VP, Biomark Developme

MERCK BeiGene Daiichi-Sankyo AMGEN MIRATI Pfizer Metamark. Roche EMD SERONO Shire MD Anderson Cancer Center SALK INSTITUTE Where cures begin. BROAD INSTITUTE zentalis NOVART

ACRIVON THERAPEUTICS AT A GLANCE



Founded 2018, IPO November 2022 (NASDAQ:ACRV)

For more information, please visit https://acrivon.com

ACRIVON PREDICTIVE PRECISION PROTEOMICS, AP3



Genomic Biomarkers are useful for patient selection in the smaller subset of cancers (<10%) with single gene driver mutations or known synthetic lethal context*

CANCER IS CAUSED BY DYSREGULATED PROTEIN ACTIVITY

Acrivon's AP3 platform directly measure the disease-driving, dysregulated proteins and is designed to enable an exact match with the drug mechanism-of-action independent of genetic alterations

(Acrivon meaning: "*Exact, Accurate*")

**Oncogenic Kinase Signaling: Blume-Jensen, P. and Hunter, T. Nature (2001)*
Synthetic lethality as an engine for cancer drug target discovery: Huang, A. et al. NatRevDrugDisc (2020)

AP3 PLATFORM ADDRESSES HIGH UNMET NEED BEYOND NGS-BASED PRECISION MEDICINE





Sources: Company Filings, ACS, CDC, NCI, Wall Street Research (2022)

AP3 PLATFORM: DRUG RESPONSE PREDICTION IN INDIVIDUAL PATIENTS





"Disease Pathway-Based Method to Generate Biomarker Panels Tailored to Specific Therapeutics for Individualized Treatments": EP 2 229 589, issued June 10, 2015; US2017/0067877A9, pending. OncoSignature® is a Registered Trademark: US Reg. No. 5,718,472; Int. Cl. 5, 42. Intl. Reg. 1382289

ACRIVON PIPELINE



Notes

ACR-368 Monotherapy	Registrational intent Phase 2 single arm trials based on predicted sensitivity to ACR-368 monotherapy in OncoSignature-positive patients
LDG Combination	Exploratory Phase 1b/2 single arm trials of ACR-368 in combination with low dose gemcitabine, or LDG, in OncoSignature-negative patients

ACR-368: A CLINICALLY ACTIVE PHASE 2 CHK1/2 INHIBITOR

- ATP-competitive inhibitor of CHK1 (0.9 nM) and CHK2 (8 nM)
- Good ADME properties, minimal drug-drug interaction (DDI) potential
- Discovered by Array Biopharma, acquired by Eli Lilly & Company
- CoM patent exp. Oct., 2030; Salt-form exp. Apr., 2037



ACR-368 (MW): 365.4



- **Durable monotherapy activity:** Platinum-resistant ovarian and squamous cell cancers (Anal and H&N)
- **Large safety database, favorable safety profile:** >1,000 patients treated (~50% mono, ~50% in combination)
- **Ideal for AP3 method:** Proven clinical activity, but requires patient responder identification to achieve sufficient ORR

CLINICAL OVERVIEW OF ACR-368 MONOTHERAPY (PAST DATA)

Indication	Trial	ORR# (confirmed)	Median DoR°	Reference
HGSOC* (BRCA wild type, primarily platinum-resistant)	Phase 2 single center (NCI)	29%	>10 months^	Lee et al, Lancet Oncology, 2018
HGSOC (BRCA wild type and mutant; platinum-resistant and refractory)	Phase 2 multi-center (Lilly)	12.1% (platinum-resistant)	5.6 months	Konstantinopoulos et al; Gynec. Oncol.: 2022
Squamous cell cancer (anal cancer, head & neck cancer [H&N])	Phase 1b multi-center (Lilly)	19% HPV+ H&N 15% anal cancer	7 months (HPV+ H&N) 12 months anal cancer	Hong et al, CCR, 2018

Dosing and Administration

- IV q14d (RP2D = 105 mg/m^2)

Safety summary

- Acceptable safety profile in >1,000 patients
  - No clinical or regulatory holds imposed across all clinical studies to date
- Primary adverse events ≥ grade 3 were hematological (manageable neutropenia and thrombocytopenia)
- Limited ≥ grade 3 non-hematological toxicities (≤7% for all AEs)
- Drug-related discontinuations <1-2%

*High grade serous ovarian cancer; ^Updated post-publication; # Overall response rate; °Duration of Response

PAST PHASE 2 TRIALS IN HIGH GRADE SEROUS OVARIAN CANCER

NCI single-center Phase 2 study (N=28)

- Heavily pre-treated patients; median 5 prior lines
- Pretreatment tumor biopsies mandated

RESULTS

- ORR 29%; mDoR >10 months (post-publication)
- No genetic correlation with $p53^{mut}$, DDR^{mut}, or CCNE1



Lee et al; Lancet Oncology: 2018

Lilly-sponsored multi-center (46 center, 8 country) Phase 2 study (N=169)

- All lines of prior therapy, BRCA wt and mt, incl. prior PARPi
- Pretreatment tumor biopsies mandated

RESULTS

- ORR 12.1% (excl. unconfirmed); mDoR =5.6 months
- No correlation with genetic alterations

N = 169 PATIENTS	COHORT DESCRIPTION	PERCENT CONFIRMED ORR (95 % C.I.)
Cohort 1 (53)	Plat resistant BRCA wt; ≥3 lines of prior therapy	11.3 (4.3 to 23.0)
Cohort 2 (46)	Plat resistant BRCA wt; < 3 lines of prior therapy	13.0 (4.9 to 26.3)
Cohort 3 (41)	Plat resistant BRCA mt, any line of therapy (must include prior PARPi)	12.2 (4.1 to 26.2)
Cohort 4 (29)	Plat refractory, any BRCA, any line of therapy	6.9 (0.8 to 22.8)

Konstantinopoulos et al; Gynec. Oncol.: 2022

- ✓ Past trials suggest unenriched all-comer ORR in HGS ovarian cancer is ~15-20%
- ✓ Durable clinical activity in most responders
- ✓ No predictive biomarkers identified, need for alternative biomarker approach (ideal for AP3)

DEVELOPMENT OF AP3-BASED PATIENT SELECTION ONCOSIGNATURE TESTS



ONCOSIGNATURE TESTS: USAGE IN THE CLINIC

Pretreatment tumor biopsy



Sample processing

Biopsy in FFPE block

Automated tumor Region-of-Interest biomarker scoring



- Pretreatment tumor biopsy test
- Compatible with 5 business days turn-around
- Offered by CDx partner under exclusive license from Acrivon

Treatment decision based on patient stratification



CONSISTENT ACR-368 ONCOSIGNATURE PERFORMANCE ACROSS PRECLINICAL STUDIES



OncoSignature®

- Prediction of the fraction of human tumors sensitive to single agent ACR-368
  - Selection rate 30-40% across lead indications
- Identification of additional human tumor types predicted sensitive to single agent ACR-368
  - Endometrial and bladder cancer
- Prediction of treatment outcome in human PDX models
  - ORR enrichment to ≥ 55%; AUC of 0.88 and 0.9
- Two separate, prospectively designed, blinded studies of biopsies from past Phase 2 trials with ACR-368 in patients with platinum-resistant ovarian cancer
  - ORR enrichment to 47% (NCI) and 58% (Lilly multi-center)

ACR-368 ONCOSIGNATURE PREDICTION OF DRUG SENSITIVITY: BIOMARKER QUANTITATION ACROSS HUMAN CANCER PATIENT SAMPLES



Tissue ID.	BM1	BM2	BM3
Fov060265	0.69	0.79	0.73
Fov050855	0.94	0.71	0.67
Fov041300	0.89	0.23	0.55
Fov060380	0.95	0.62	0.51
Fov060050	0.85	0.23	0.51
Fov041285	0.69	0.19	0.5
Fov100142	0.47	0.76	0.47
Fov050764	0.82	0.22	0.47
Fov041267	0.4	0.36	0.36
Fov100146	0.84	0.57	0.26
Fov060382	0.44	0.45	0.22
Fov041269	0.37	0.21	0.2
Fov060302	0.29	0.22	0.15
Fov020067	0.89	0.38	0.09
Fov100003	0.9	0.89	0.08
Fov050700	0.17	0.17	0.07
Fov050139	0.63	0.66	0.05
Fov041138	0.36	0.11	0.05
Fov060152	0.24	0.3	0.03
Fov030062	0.57	0.14	0.02
Fov060133	0.94	0.43	0.01
Fov050666	0.93	0.38	0.01
Fov060371	0.88	0.93	0
Fov020497	0.61	0.43	0
Fov010706	0.54	0.14	0
Fov020386	0.11	0.09	0.12
Fov050734	0.11	0.06	0.08
Fov040872	0.23	0.04	0.36
Fov050659	0.29	0.01	0.02
Fov060293	0.42	0	0
Fov060210	0.1	0.1	0
Fov050840	0.07	0.29	0.01
Fov040855	0.05	0	0.22
Fov050816	0.04	0.33	0.12
Fov060355	0.04	0.27	0
Fov010252	0.03	0.17	0.02
Fov010682	0.03	0.03	0
Fov060553	0.03	0.02	0.03
71768C3	0.02	0	0
Fov150230	0	0.36	0.12
Fov060308	0	0	0

BIOPSY STUDY 1: SUBSTANTIAL RESPONSE AND PFS BENEFIT IN PREDICTED RESPONDERS (BLINDED, PROSPECTIVELY DESIGNED STUDY)

- Available pretreatment tumor biopsies from past phase 2 trials at NCI with ACR-368 in platinum-resistant ovarian cancer were obtained
- OncoSignature scores were generated **blinded to treatment outcome** at Acrivon and analyzed by **3rd party biostatistician** in **prospectively designed** study





	mPFS (days)
All Predicted R	238.(
All Predicted NR	66.5
SD in predicted R	238.(
SD in predicted NR	108.(

OncoSignature®

Result: ORR ~47%; mPFS = 7.9 months

TWO ADDITIONAL HIGH UNMET NEED SOLID CANCERS PREDICTED ACR-368-SENSITIVE THROUGH HUMAN TUMOR SAMPLE SCREENING

HGS Ovarian



OncoSignature-positive = 30%
(ORR in past trials: 12+% and 29%)

Sq. NSCLC



OncoSignature-positive = 0%
(ORR in past trial: 0%)

Bladder cancer



OncoSignature-positive = 30-50%

Endometrial cancer



OncoSignature-positive = 30-40%

TWO ATTRACTIVE ACR-368-SENSITIVE CANCER TYPES IDENTIFIED



ACR-368 OncoSignature screening of human cancer samples

A SUBSET OF ENDOMETRIAL AND BLADDER PDX MODELS ARE HIGHLY SENSITIVE TO ACR-368



AP3 UNCOVERS ACTIONABLE ACR-368 RESISTANCE MECHANISMS UNBIASED AND INDEPENDENT OF GENETIC INFORMATION



Data suggest that gemcitabine might be a rational combination to overcome DDR suppression

LOW DOSE GEMCITABINE SENSITIZES OVARIAN CANCER CELL LINES TO ACR-368











Bliss Synergy score:

- <-10: Drug interaction is likely antagonistic
- -10 to 10: Drug interaction is likely additive
- >10: Drug interaction is likely synergistic

ENROLLING AND DOSING ACR-368 IN THREE HIGH UNMET NEED INDICATIONS: OVARIAN, ENDOMETRIAL AND BLADDER CANCER

- RP2D of ACR-368 based on predicted sensitivity using our ACR-368 OncoSignature Assay run by our CDx partner
- 58 sites currently activated[1]
- Key opinion leaders, some with extensive experience using ACR-368 from previous trials are actively participating



FDA Fast Track Designation granted May 8, 2023 for ACR-368 monotherapy in OncoSignature-positive patients with Platinum-Resistant Ovarian Cancer and Endometrial Cancer

[1]https://clinicaltrials.gov/ct2/show/NCT05548296

ENCOURAGING INITIAL CLINICAL OBSERVATIONS

- Consistent with the extensive experience and tolerability profile from past trials, drug-related adverse events are primarily hematological, reversible, and manageable
- In the limited number of patients evaluated by imaging, preliminary evidence of clinical activity has been observed in OncoSignature-positive patients across all three tumor types treated with single agent ACR-368 at RP2D
- Consistent with AP3-predicted tumor sensitivity, early imaging-based evidence of clinical activity across all three tumor types was also observed in OncoSignature-negative patients treated with ACR-368 at RP2D and LDG during the dose escalation phase

As of November 3, 202

WEE1 AND PKMYT1 VALIDATED CANCER TARGETS: IDEAL FOR AP3 APPROACH

- WEE1 and PKMYT1 regulate S and G2-M cell cycle checkpoints to ensure proper DNA replication and mitotic completion through phosphorylation and inhibition of CDK2 and CDK1 and CDK1, respectively
- WEE1 inhibition propagates genomic instability by premature DNA replication and cell cycle progression, resulting in mitotic catastrophe
- PKMYT1 inhibition results in premature mitotic entry and cell death
- Strong preclinical data and emerging clinical data:
  - Adavosertib (AstraZeneca)
  - Debio0123 (Debiopharm)
  - Azenosertib (Zentalis Pharmaceuticals)
  - SGR-3515 (preclinical, Schrödinger)
  - Lunresertib (Repare Therapeutics)



Ghelli Luserna di Rorà et al. J. Hematol Oncol, 2020

- ✓ Single agent clinical activity (WEE1 and PKMYT1)
- ✓ Synergy identified with dual inhibition, potential for strong monotherapy clinical activity
- ✓ Correlation with genetic alterations challenging, CCNE1 association being explored by others
- ✓ Acrivon intends to leverage OncoSignature for optimal patient selection

INTERNAL PIPELINE: ADVANCING DEVELOPMENT CANDIDATE ACR-2316 AND OTHER DDR PROGRAMS - LEVERAGING AP3

Rationale

- *Leveraging our AP3 patient selection platform for high clinical POS*
- *Potentially optimal profile for monotherapy clinical development*

ACR-2316 and other DDR programs

- >40 high resolution co-crystals (1.5-3.1 Å) and AP3-driven SAR
- Novel WEE1- and PKMYT1-selective structural series and lead candidates
- Optimal selectivity profiles generated based on AP3 profiling

ACR-2316 advancing in IND-enabling studies



- High resolution co-crystals with WEE1 and PKMYT1
- Novel, potent dual inhibitor (single digit nM potency)
- Designed to overcome WEE1 and PKMYT1 single inhibitor resistance
- Potent, selective single agent activity

High throughput AP3 profiling



AP3 used for biologically relevant selectivity profiling

EXECUTIVE SUMMARY: ACR-2316 DEVELOPMENT CANDIDATE

A selective dual WEE1/ PKMYT1 inhibitor optimized using AP3 for potent single agent activity

Accelerating IND-enabling studies and planning for monotherapy clinical development

- AP3-based SAR optimization facilitated by co-crystallography with WEE1 and PKMYT1
  - Quantitative visualization of drug-regulated global protein activity in cells not possible with standard methods
  - Unbiased detection of WEE1 inhibitor-induced resistance mechanisms overcome by balanced PKMYT1 inhibition
- Single digit nM WEE1 inhibition with carefully optimized ratio of PKMYT1 inhibition in cells
- Superior target selectivity and cell growth inhibition across human tumor cell lines vs clinical benchmark WEE1 and PKMYT1 inhibitors
- Superior preclinical anti-tumor activity in tumor-bearing mice, including tumor regression, surpassing that of clinical benchmark molecules
- In vitro ADME, PK, and oral bioavailability profiles meet pre-specified development candidate criteria
- On track for Q4 2024 IND with safety observed in MTD studies consistent with predicted desirable human exposure
- Generating ACR-2316-OncoSignature test for indication finding and to guide monotherapy clinical development

DUAL WEE1/PKMYT1 INHIBITOR ACR-2316 DEMONSTRATES STRONG POTENCY AND SELECTIVITY







Dual inhibitor show potent cell cycle effects with pronounced S-G2/M accumulation



100 nM, 24 hour

ACR-2316 SHOWS SUPERIOR ACTIVITY VS BENCHMARKS ACROSS ALL HUMAN TUMOR CELL LINES TESTED



PKMYT1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 2 IC50 (nM)	ACR-2316 IC50 (nM)
340	39	47	7



PKMYT1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 2 IC50 (nM)	ACR-2316 IC50 (nM)
> 1000	> 1000	> 1000	207



PKMYT1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 2 IC50 (nM)	ACR-2316 IC50 (nM)
345	130	136	24



PKMYT1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 1 IC50 (nM)	WEE1 Inhibitor 2 IC50 (nM)	ACR-2316 IC50 (nM)
967	471	533	40

Example: Ovarian human cancer cell lines

19 ovarian and other human tumor cell lines tested to date

ACR-2316 IS HIGHLY POTENT ACROSS HUMAN TUMOR CELL LINES AND PATIENT-DERIVED *EX VIVO* TUMOR MODELS



ACR-2316 DEMONSTRATES POTENT MONOTHERAPY ANTI-TUMOR ACTIVITY IN TUMOR-BEARING MICE

ACR-2316 anti-tumor activity (QDx7; PO)



ACR-2316 anti-tumor activity (5d on/2d off; PO)



ACR-2316 demonstrates potent anti-tumor activity, including tumor regression, compared to benchmark WEE1 and PKMYT1 inhibitors

ACR-2316 EMERGING SAFETY PROFILE FROM PRECLINICAL ANIMAL STUDIES APPEARS PROMISING

Mice:

- ACR-2316 is well-tolerated at target doses up to ≤60 mg/kg daily oral dosing resulting in tumor regression in xenograft mouse models
- No obvious anemia, neutropenia, or thrombocytopenia, moderate reticulopenia, monocytopenia, and lymphopenia

Rat and dog MTD:

- MTD ≥ 30 mg/kg in both species
- Plasma PK exposure consistent with projected human exposure levels required for potential anti-tumor activity
- Reversible hematological effects (white blood cells), no thrombocytopenia

STREAMLINED AP3-BASED BIOLOGICAL SAR OPTIMIZATION FOR SINGLE AGENT ACTIVITY OF PRECLINICAL PROGRAMS

Drug treatment

Proteolysis
P-peptide enrichment



Peptide clean up

Ultra high resolution
P-proteomic profiling



Direct DIA analysis

High resolution and throughput MS-based P-proteomics

Quantitative mapping (>35,000 phospho-sites covering >4,500 proteins)



Drug-regulated phospho-sites and biological process enrichment

Drug-regulated pathway activity mapping and reconstitution



Week 0

Turnarour
<2 week

Week2

Proprietary pipe for automated AP3 analyses with actionable results

AP3: TIGHT, HIGH-RESOLUTION DATA WITH DEEP COVERAGE

35388 p-sites

15733 p-sites

QC MS Data → Data Clean Up → QC Processed Data → Volcano Plots → Hierarchical Clustering → Consensus Sequence Motif → Kinase Inference → Pathway Enrichment → Functional Annotation → Network Mapping → Biomarkers











- ✓ Acrivon proprietary compound data (~30 million data points per experiment); dozens of compounds profiled
- ✓ Miniaturized, high throughput, scalable: <2 weeks turn-around, automated AI computational analyses in 1 day
- ✓ Actionable results: Resistance mechanisms, rational combinations, drug-tailored OncoSignature patient selection

AP3 REVEALS DRUG-REGULATED KINASE ACTIVITY IN INTACT CELLS NOT DETECTABLE BY STANDARD METHODS



OPTIMIZED DUAL INHIBITORS SHOW DESIRABLE PATHWAY EFFECTS

Optimized dual WEE1 and PKMYT1 inhibitors affect cell cycle and canonical MAPK pathways in desirable manner



*Clinical-stage selective WEE1 and PKMYT1 inhibitors

AP3-DERIVED DUAL POTENCY OPTIMIZATION TO OVERCOME WEE1 INHIBITOR RESISTANCE: RECIPROCAL QUENCHING



AP3 RECIPROCAL QUENCHING REVEALS OPTIMAL TARGET POTENC PROFILE FOR DUAL WEE1/PKMYT1 INHIBITOR



ACR-2316 MEETS PRE-SPECIFIED DEVELOPMENT CANDIDATE CRITERIA

	Target	ACR-2316
MOA	• AP3 phosphoproteomics-based, optimized MOA; selective, dual WEE1/PKMYT1 inhibition	✓
Potency	• In vitro kinase activity, $IC_{50} \leq 10$ nM • Potent *in cell* target engagement in optimized ratio • Activity across sensitive human tumor cell lines, IC_{50} <20 nM	✓ ✓ ✓
Selectivity	• Kinase panel profiling – highly selective (kinome selectivity) • AP3 profiling confirms desirable CDK and PLK activation for mitotic catastrophe/apoptosis	✓ ✓
ADME/PK	• Orally bioavailable • T½ suitable for once/day dosing	✓ ✓
In vitro safety	• Low in vitro hERG (>10 μM) and CYP inhibition and induction (>1 μM)	✓
Solubility	• > 50 μM for active compounds	✓
PPB	• < 90%	✓
In vivo efficacy	• Demonstrated potent target engagement intratumorally in vivo • Potent single agent activity in CDX models	✓ ✓

EXPEDITING ACR-2316 TOWARDS CLINICAL MONOTHERAPY DEVELOPMENT

A novel, AP3-enabled, internally discovered dual WEE1 / PKMYT1 inhibitor

Rational Design

- Co-crystallography-driven programs specifically optimized via AP3 SAR
- AP3-enabled design with optimized WEE1 / PKMYT1 target engagement properties and ratio
- AP3-based optimization of functional target profile ensuring PLK and CDK1/2-driven mitotic catastrophe

Superior Profile

- Demonstrated preclinical superiority in target selectivity / potency and vs. benchmark WEE1 and PKMYT1 compounds
- Stronger anti-tumor activity in tumor bearing mouse models vs. benchmark WEE1 and PKMYT1 compounds

Streamlined Development

- Aiming for expedited monotherapy development (clinically validated targets)
- Rapidly advancing towards IND (expected Q4 2024)
- OncoSignature test in development for indication finding and patient selection
- Dose optimization (Project Optimus) to be guided by drug target engagement (BM2)

AP3: BROAD APPLICABILITY AND UNTAPPED POTENTIAL



AP3 IS BROADLY APPLICABLE ACROSS DRUG DISCOVERY AND DEVELOPMENT



Clinical Biomarkers
Predictive OncoSignature tests



Indication Finding
Sensitive tumor types



Drug Discovery SAR
Optimal target selectivity

AP3

Informs in-licensing
AP3 profiling of candidates

Intellectual Property
De novo exclusivity & protection against generics

Resistance Mechanisms
Rational drug combinations



Predicted Responder

PD Markers
~6,000 per compound

THE AP3 APPROACH IS MODALITY AND DISEASE AGNOSTIC



FINANCIAL HIGHLIGHTS AS OF Q3 2023

Cash and marketable securities	Projected runway into	Fully Diluted Shares Outstanding
$142.1M	H2'25	27.6M
Balance sheet 30-Sept-2023	**Current operating plan, assuming no additional financing**	**Shares and equity grants outstanding 30-Sept-2023**

Unaudited.

ACRIVON ADDRESSABLE MARKETS (US & EU INCIDENCE)

Prioritized indications for single agent ACR-368



Potential additional indications for single agent ACR-368





All cancers US and Europe
Est. >6.3M cases/year

- ~30% (N = 223,000) of prioritized indications predicted sensitive to single agent ACR-368
- WEE1 and/or PKMYT1 inhibitor combinations with ACR-368 might further expand addressable fraction within sensitive tumor types

US cancer stats are based on ACS 2022 publication and subtype estimation from literature; EU cancer stats are based on IARC 2020 publication and subtype estimation from literature.
Cancers with DDR stress are estimated to be 67% which is calculated from MSK-IMPACT patient samples with DDR relevant mutations and CNVs, such as TP53, KRAS, CCNE1, etc.

APPENDIX

TEAM HAS PIONEERED OUTCOME-PREDICTIVE QUANTITATIVE PROTEOMIC MULTIPLEX IN SITU TEST

Prostate cancer 8-marker biopsy test developed and launched by Founding team



- ProMark®: Marketed, automated *in situ* proteomic test for human outcome prediction included under NCCN guidelines
- Founding team: Has pioneered p-proteomics and quantitative multiplex imaging including double-blinded clinical validation*

Ideal test	Protein multiplex *in situ* test	Current CDx tests
Quantitative and automated	✓	(✓)
Validated Abs and reagents	✓	(✓)
Drug target and pathway activation context	✓	
Biomarkers measured in relevant region on tumor biopsy	✓	
Imaging algorithm (tissue pattern)	✓	
Addresses tumor heterogeneity	✓	
Double-blinded, prospective validation	✓	(✓)

*Blume-Jensen et al: Development and clinical validation of an *in situ* biopsy-based multimarker assay for risk stratification in prostate cancer. Clinical Cancer Research (2015)

PROOF-OF-CONCEPT FOR PROTEIN BIOMARKER SIGNATURE: MARKETED, OUTCOME-PREDICTIVE MULTIPLEX CANCER TEST

Biology of Human Tumors

Clinical Cancer Research

(2015)

Development and Clinical Validation of an *In Situ* Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer

Peter Blume-Jensen[1], David M. Berman[2], David L. Rimm[3], Michail Shipitsin[1], Mathew Putzi[4], Thomas P. Nifong[1], Clayton Small[1], Sibgat Choudhury[1], Teresa Capela[1], Louis Coupal[5], Christina Ernst[1], Aeron Hurley[1], Alex Kaprelyants[1], Hua Chang[1], Eldar Giladi[1], Julie Nardone[1], James Dunyak[1], Massimo Loda[6], Eric A. Klein[7], Cristina Magi-Galluzzi[8], Mathieu Latour[9], Jonathan I. Epstein[10], Philip Kantoff[6], and Fred Saad[9]

- Third-party blinded clinical validation, bioinformatic analysis (U. Montreal)
- Validation of locked ProMark™ test on single institution biopsy cases (N=274)
- Secondary validation on multi-center biopsy cohort (N=359) for clinical use indication
- Marketed test included under NCCN Guidelines and Medicare coverage

PIONEERING PHOSPHO-PROTEOMICS STUDY IDENTIFIES NOVEL PI3'K PATHWAY INHIBITOR BIOMARKERS

Science Translational Medicine
AAAS

Sci Transl Med
2: 1-14 (2010)

RESEARCH ARTICLE

CANCER DRUG DEVELOPMENT

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Jannik N. Andersen,[1]* Sriram Sathyanarayanan,[1]* Alessandra Di Bacco,[1] An Chi,[1] Theresa Zhang,[1] Albert H. Chen,[1] Brian Dolinski,[1] Manfred Kraus,[1] Brian Roberts,[1] William Arthur,[2] Rich A. Klinghoffer,[1]† Diana Gargano,[1]§ Lixia Li,[1] Igor Feldman,[1] Bethany Lynch,[1] John Rush,[3] Ronald C. Hendrickson,[4,5] Peter Blume-Jensen,[1,5]‖ Cloud P. Paweletz[1]

Editorial Highlights:



VOLUME 28 NUMBER 10 OCTOBER 2010 NATURE BIOTECHNOLOGY

Tracing cancer networks with phosphoproteomics

David B Solit & Ingo K Mellinghoff

A mass-spectrometry approach for identifying downstream events in cancer signaling pathways may help to tailor therapies to individual patients.



Science Translational Medicine
AAAS

TOWARD CUSTOMIZING TUMOR TREATMENT

Just as our view of Earth has become increasingly global, cells are now seen as complex networks of interacting and intersecting signaling pathways rather than a collection of regulated genes.



Nature Reviews Cancer | AOP, published online 19 August 2010; doi:10.1038/nrc2922

A discovery strategy for novel cancer biomarkers

OLSEN LAB-EXAMPLES OF DEEP PROTEOMICS DRUG PROFILING

Science Signaling (2018)

ALK-i : LDK378, TAE684, crizotinib, lorlatinib.

SCIENCE SIGNALING | RESEARCH RESOURCE

CANCER

Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma

Cell Reports (2018)

SHP2-i: SHP099 -allosteric inhibitor.

Large-Scale Phosphoproteomics Reveals Shp-2 Phosphatase-Dependent Regulators of Pdgf Receptor Signaling

Cell Reports (2017)

CHK1-i: SCH900776, **ATM-i:** KU55933

Proteomics Reveals Global Regulation of Protein SUMOylation by ATM and ATR Kinases during Replication Stress

Cell Reports (2017)

CDK7-i: THZ-1

Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer

Cell Systems (2017)

Deepest proteome resolution of a human cell to date

An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes

Cell (2019)

Functional mapping of differential signaling by RPTK mutants

Oncogenic Mutations Rewire Signaling Pathways by Switching Protein Recruitment to Phosphotyrosine Sites

Nature Communications (2020)

Highest throughput, sensitivity, and scalability to date

ARTICLE OPEN

Rapid and site-specific deep phosphoproteome profiling by data-independent acquisition without the need for spectral libraries

Nature Communications (2021)

Subcellular compartmental proteomics

ARTICLE OPEN

Spatial-proteomics reveals phospho-signaling dynamics at subcellular resolution

Nature Communications (2021)

Clinically actionable resistance mechanisms

ARTICLE OPEN

Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures

ONGOING (MULTICENTER): Profiling of DDR and core kinase pathway inhibitors (>45)



ADVISORS AND COLLABORATORS

SAB

George Demetri, M.D., FACP, FASCO, FAACR

Professor, Harvard Med. School, Dir. Dana-Farber Cancer Institute & Ludwig Center, Boston

- Leader in Precision Oncology
- Key contributor to development and rapid approvals of Gleevec, Sutent, Stivarga, Zelboraf, Votrient, and Yondelis

Robert Abraham, Ph.D.

EVP, Head Cancer Biology, Odyssey Therapeutics

Adj. Prof. , Burnham Inst.
Adj. Prof. UCSD

- Expert in signal transduction-based R&D
- Previously SVP and WW Head, Oncology R&D, Pfizer
- VP, Oncology Res., Wyeth
- Professor, Burnham Institute
- Professor, Duke University

Timothy Yap, M.B.B.S., Ph.D., F.R.C.P.

Associate Prof., MD Anderson Cancer Center, Medical Director, Inst. for Applied Cancer Science

- Expert on DDR accelerated clinical development and predictive biomarkers
- Previously oncologist Royal Marsden, London and Inst. Cancer Res, London
- Lead/P.I. on numerous DDR trials

David Berman, M.D., Ph.D.

Professor, Director, Queen's Cancer Res. Inst., Ontario Canada

- GU Pathologist; bladder cancer expert
- Expert on protein biomarkers and quantitative tissue imaging
- Academic lead on ProMark®

Jesper V. Olsen, Ph.D.

Academic Co-Founder

Professor, Novo-Nordisk Foundation Protein Center, Cph. University

- Recognized pioneer and leading authority in phosphoproteomics and proteomic systems analyses
- Top 0.1% most cited scientist in protein sciences

Jung-Min Lee, M.D.

NCI Collaborator

Investigator, Lasker Clinical Research Scholar, NCI

- Expert on women's cancers and DNA damage response (DDR)
- Lead and co-PI on numerous HGSOC &TNBC trials
- Lead PI on ACR-368 platinum-resistant ovarian trials

AP3 IS APPLICABLE ACROSS DRUG DEVELOPMENT STAGES



AP3 ANALYSIS: ACR-2316 REGULATES CELL CYCLE AND MITOSIS MORE POTENTLY THAN BENCHMARK WEE1 INHIBITOR



AP3 ANALYSIS: ACR-2316 REGULATES CELL CYCLE AND MITOSIS MORE POTENTLY THAN BENCHMARK PKMYT1 INHIBITOR



Article

Cell Reports

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Graphical abstract



Authors

Kristina B. Emdal, Nicolàs Palacio-Escat, Caroline Wigerup, ..., Kristina Masson, Peter Blume-Jensen, Jesper V. Olsen

Correspondence

pub.saez@uni-heidelberg.de (J.S.-R.), kmasson@acrivon.com (K.M.), pblumejensen@acrivon.com (P.B.-J.), jesper.olsen@cpr.ku.dk (J.V.O.)

In brief

Emdal et al. combine phosphoproteomics of samples from patients with AML and functional phosphosite scoring to uncover clinically actionable molecular context for selinexor efficacy. Sensitivity to selinexor correlates with functional p53 and is enhanced with nutlin-3a, while resistance is associated with dysregulated AKT-FOXO3 signaling and overcome by combining with MK-2206.

Using spatial phosphoproteomics (*Nat. Commun.*, 2021) Acrivon's AP3 platform can uncover single agent sensitivity and rational drug combinations for targets with complicated mechanism of action

Cell Reports, August 9, 2022

ELI LILLY ACR-368 HIGH LEVEL LICENSE TERMS

- In-licensing completed 27 January 2021
  - WW exclusive rights with rights to sub-license
  - $5M up front and low single digit percentage equity subject to ordinary dilution going forward
  - Aggregate development and commercial milestone payments of up to $168M, of which $5M is due prior to NDA
  - Tiered percentage royalty on annual net sales ranging from low single-digit up to a maximum of 10% subject to certain specified reductions
  - Drug product as well as drug substance sufficient to treat several hundred patients
  - Limited right of first negotiation expiring 45 days upon completion of certain clinical milestones